Drug · CHEMBL667
ACETYLCHOLINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ACETYLCHOLINE. Drugs and targets, record CHEMBL667. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL667
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CHRM3 | Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M3 agonist | AGONIST | https://conductscience.org/library/genes/1131 |
Source ChEMBL
Diseases14
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 14Source Open Targets
See all 14 diseasesTrials35
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00166166 | Endothelial Hyperpolarization in Humans | Phase 2 | 174 | 2015-05-13 | acetylcholine | Its name | ClinicalTrials.gov |
| NCT04374500 | Leptin Infusion and Endothelial Vasomotor Response | Early phase 1 | 103 | 2020-07-17 | acetylcholine | Its name | ClinicalTrials.gov |
| NCT03953326 | HeartPhone Cancer Survivors Trial 2019 | Phase 1/2 | 2 | 2026-02-27 | acetylcholine | Its name | ClinicalTrials.gov |
| NCT02966665 | : Vascular Function in Health and Disease | Phase 1 | 420 | acetylcholine | Its name | ClinicalTrials.gov | |
| NCT05193968 | Hot Flashes and Neurovascular Function in Women | 120 | acetylcholine | Its name | ClinicalTrials.gov | ||
| NCT00160888 | Vasoreactivity in Carriers of Genetic Polymorphisms | Phase 1 | 100 | acetylcholine | Its name | ClinicalTrials.gov | |
| NCT00253929 | Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia | 100 | acetylcholine | Its name | ClinicalTrials.gov | ||
| NCT00009581 | Nitric Oxide to Improve Blood Flow in Sickle Cell Disease | Phase 2 | 65 | acetylcholine | Its name | ClinicalTrials.gov | |
| NCT06520982 | Early Neurovascular Adaptations in Aging Women | Early phase 1 | 64 | acetylcholine | Its name | ClinicalTrials.gov | |
| NCT06499844 | Comparing Approaches to Assess Nitric Oxide-dependent Cutaneous Vasodilation | Early phase 1 | 56 | acetylcholine | Its name | ClinicalTrials.gov |
1 to 10 of 35
See all 35 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Healthy Controls vs Risk Factors: serious adverse events | 0 of 103 | 0 of 71 | 174 | NCT00166166 |
Source Trial comparisons
Papers from its trials19
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL667
GET https://conductscience.org/api/drugs/v1/CHEMBL667/trials?page=2